{"id":770848,"title":"Regional differences in access to direct-acting antiviral treatments for hepatitis C across Ontario: A cross-sectional study, CCDR 48(4) - Canada.ca","sourceCode":"phac","sourceName":"Public Health Agency of Canada","language":"en","captureDate":"2026-03-06","captureTimestamp":"2026-03-06T03:31:06.481000+00:00","jobId":7,"originalUrl":"https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2022-48/issue-4-april-2022/differences-hep-c-treatment-across-ontario.html","snippet":"Differences of hepatitis C treatment across Ontario Download this article as a PDF Published by: The Public Health Agency of Canada Issue: Volume 48-4, April 2022: First Nations Health Date published: April 2022 ISSN: 1481-8531 Subscribe to CCDR Information for authors About CCDR…","rawSnapshotUrl":"/api/snapshots/raw/770848","browseUrl":"https://replay.healtharchive.ca/job-7/20260306033106/https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2022-48/issue-4-april-2022/differences-hep-c-treatment-across-ontario.html#ha_snapshot=770848","mimeType":"text/html","statusCode":200,"captureBackend":"playwright_warc","captureFidelity":"fallback"}